Friday, January 30, 2026

Blasting North Korea: U.S., South JKorea and Japan Take a Stand at ASEAN Summit

Cho Tae Yul, South Korea's Minister of Foreign Affairs, will attend the ASEAN-related meetings on the 26th and 27th along with ...

Tired of the Mental Spiral? ‘Women Who Think Too Much’ Has Answers

Susan Nolen-Hoeksema explores overthinking in women, offering insights and techniques to break free and reclaim happiness.

From CES 2026 to 200 Countries: How Korean AI Startups Are Testing Global Demand

Wadiz supports global expansion for innovative Korean companies at CES 2026, offering consulting and resources for market entry.

Tag: Eli Lilly

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

Nvidia and Eli Lilly: How AI is Revolutionizing Drug Development in 2026

Nvidia partners with Eli Lilly to enhance AI in drug development, aiming to revolutionize the biotech industry.

Rising Use of GLP-1 Drugs May Be Linked to Rare Pancreatitis Cases, Study Finds

Reports of acute pancreatitis linked to GLP-1 diabetes drugs surge in the UK, prompting investigations and conflicting academic findings.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

Top News

- Our Sponsors Ad -

Follow us